Buffing Up on New Oral UC Therapies
What You Need to Know
Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease.
Choden T, et al. Gastroenterol Hepatol (NY). 2022;18(5):265-271.
Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis—a unique therapeutic target in inflammatory bowel disease.
Wang J, et al. Aliment Pharmacol Ther. 2022;55(3):277-291.
Ozanimod as induction and maintenance therapy for ulcerative colitis.
Sandborn WJ, et al. N Engl J Med. 2021;385(14):1280-1291.
P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension.
Panaccione R, et al. J Crohns Colitis. 2023;17(suppl 1):i534-i535. DOI: 10.1093/ecco-jcc/jjac190.0535.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ, et al. Lancet. 2023;401(10383):1159-1171.
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.
Sugahara K, et al. Br J Pharmacol. 2017;174(1):15-27.
Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists.
Agrawal M, et al. Gastroenterology. 2021;161(1):47-65.
STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.
Turner D, et al. Gastroenterology. 2021;160(5):1570-1583.
A treat-to-target update in ulcerative colitis: a systematic review.
Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.
From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.
DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study.
Danese S, et al. J Crohns Colitis. 2023;17(suppl 1):i101-i102. DOI: 10.1093/ecco-jcc/jjac190.0077.
Defining success in treating patients with inflammatory bowel disease.
Theede K, Burisch J. Expert Rev Clin Immunol. 2017;13(7):645-647.
Additional Activities in HIV
Answers to Everyday Practice Challenges in HIV Medicine: Volume 2 – A Phone-a-Friend Peer Consult Series
Optimizing HIV and HCV Treatment and Prevention Among People Experiencing Homelessness: An Expert Panel Discussion
Applying HIV Advances in Practice: What the Pharmacist Needs to Know
Guidelines
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.
Raine T, et al. J Crohns Colitis. 2022;16(1):2–17.
ACG Clinical Guideline: Ulcerative Colitis in Adults.
Rubin DT, et al. Am J Gastroenterol. 2019;114(3):384-413.
American Gastroenterological Association Institute Clinical Practice Guideline on the Management of Moderate to Severe Ulcerative Colitis.
Feuerstein JD, et al. Gastroenterology. 2020;158(5):1450-1461.
Patient Resources
American College of Gastroenterology
American Gastroenterological Association
Crohn’s and Colitis Foundation
European Crohn’s and Colitis Organisation
National Institute of Diabetes and Digestive and Kidney Diseases
Buffing Up on New Oral UC Therapies: What You Need to Know
A CME Circuit Training™ Activity
| Faculty: | Florian Rieder, MD |
| Release: | 05/17/2023 |
| Expiration: | 05/17/2024 |
